News for Jiangsu Nhwa Pharmaceutical Co., LTD (002262.SZ)

The pharmaceutical industry is experiencing rapid growth due to rising healthcare spending, an aging population, several technological advancements, and a favorable regulatory environment. Thus, it could be ideal to invest...

Chicago, Nov. 15, 2023 (GLOBE NEWSWIRE) -- The Global Pharmaceutical Grade Lithium Carbonate Market is projected to grow from USD 141 million in 2023 to...

Company previously announced statistically significant topline TRV045 data from two proof-of-concept studies evaluating S1PR mechanism of action and CNS...

SkyQuest projects that the general anesthesia drugs market will attain a USD 7.7 billion value by 2030, with a CAGR of 3.5% over the forecast period...

Trevena Announces Receipt of Milestone Payment From Partner in China Jiangsu Nhwa Pharmaceutical

OLINVYK receives regulatory approval in China, triggering $3 million milestone payment from Company’s China partner Jiangsu Nhwa Pharmaceutical Company...

Trevena’s partner, Jiangsu Nhwa, receives approval from Chinese National Medical Products Administration (NMPA) Approval achieves $3 million milestone to...

Company announces initial topline OLINVYK data including GI and cognitive outcomes, and length of stay data from ~200 patient real-world clinical outcomes...

CHESTERBROOK, Pa., March 31, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and...

Trevena Announces Submission of New Drug Application in China for OLINVYK® by its Partner Jiangsu Nhwa Pharmaceutical -- Submission supported by data from a... | January 27, 2022

DUBLIN, July 2, 2021 /PRNewswire/ -- The